Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta : A Systematic Review
作者： Ester B.G. Rijks , Bart C. Bongers , Marloes J.G. Vlemmix , Annemieke M. Boot , Atty T.H. van Dijk
DOI: 10.1159/000381713
关键词:
摘要: Background/Aims: To systematically assess contemporary knowledge regarding the effectiveness and safety of bisphosphonates (BPs) in children with osteogenesis imperfecta (OI). Methods: PubMed/MEDLINE, Embase, Cochrane were searched for eligible articles up to June 2014. Studies inclusion (randomized) controlled trials assessing effects BPs OI. Methodological quality was assessed independently by 4 reviewers using Collaboration's tool risk bias. Results: Ten studies (519 children) included. Four (40%) showed a low All investigating lumbar spine areal bone mineral density indicated significant increase as result BP treatment. Most observed decrease fracture incidence. The most frequently reported adverse events gastrointestinal complaints, fever, muscle soreness. A (bone) pain due treatment more than half studies. measuring urinary markers resorption decrease. majority intravenous projection area, whereas oral did not. Conclusions: Treatment or OI results an seems be safe well tolerated.
narcis.nl
researchgate.net 
core.ac.uk 参考文章(50)
Kerry Dwan, Carrie A Phillipi, Robert D Steiner, Donald Basel, Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database of Systematic Reviews. ,vol. 10, pp. 0- 0 ,(2016) , 10.1002/14651858.CD005088.PUB4
Franco Antoniazzi, Giorgio Zamboni, Silvana Lauriola, Luisa Donadi, Silvano Adami, Luciano Tatò, Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. The Journal of Pediatrics. ,vol. 149, pp. 174- 179 ,(2006) , 10.1016/J.JPEDS.2006.03.013
L.A. DiMeglio, L. Ford, C. McClintock, M. Peacock, Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone. ,vol. 35, pp. 1038- 1045 ,(2004) , 10.1016/J.BONE.2004.07.003
Elena Monti, Monica Mottes, Paolo Fraschini, PierCarlo Brunelli, Antonella Forlino, Giacomo Venturi, Francesco Doro, Silvia Perlini, Paolo Cavarzere, Franco Antoniazzi, Current and emerging treatments for the management of osteogenesis imperfecta. Therapeutics and Clinical Risk Management. ,vol. 6, pp. 367- 381 ,(2010) , 10.2147/TCRM.S5932
Christof Land, Frank Rauch, Kathleen Montpetit, Joanne Ruck-Gibis, Francis H. Glorieux, Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. The Journal of Pediatrics. ,vol. 148, pp. 456- 460 ,(2006) , 10.1016/J.JPEDS.2005.10.041
Frank Rauch, Craig F Munns, Christof Land, Moira Cheung, Francis H Glorieux, Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. Journal of Bone and Mineral Research. ,vol. 24, pp. 1282- 1289 ,(2009) , 10.1359/JBMR.090213
William G. Cole, Advances in osteogenesis imperfecta. Clinical Orthopaedics and Related Research. ,vol. 401, pp. 6- 16 ,(2002) , 10.1097/00003086-200208000-00003
I Banerjee, GJ Shortland, WD Evans, John Welbourn Gregory, Osteogenesis imperfecta and intravenous pamidronate Archives of Disease in Childhood. ,vol. 87, pp. 562- a ,(2002) , 10.1136/ADC.87.6.562-A
A. Goulding, I. E. Jones, R. W. Taylor, P. J. Manning, S. M. Williams, More Broken Bones: A 4‐Year Double Cohort Study of Young Girls With and Without Distal Forearm Fractures Journal of Bone and Mineral Research. ,vol. 15, pp. 2011- 2018 ,(2000) , 10.1359/JBMR.2000.15.10.2011
Nick Bishop, Characterising and treating osteogenesis imperfecta Early Human Development. ,vol. 86, pp. 743- 746 ,(2010) , 10.1016/J.EARLHUMDEV.2010.08.002